10 completed, 9 terminated, 4 withdrawn, 3 active not recruiting. 27 Phase 2, 9 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Completed 10, Terminated 9, Withdrawn 4, Active not recruiting 3, Recruiting 1 |
| Phase 1 | 9 | Completed 4, Terminated 3, Active not recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow INCB039110: new trials by email Literature Review of INCB039110 trials Research Report on INCB039110
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2022-12-29 | 2026-10-14 |
| Itacitinib for the Prevention of Graft Versus Host Disease Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide - Hematologic and Lymphocytic Disorder | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 31 | 2022-01-11 | 2026-10-07 |
| Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) ASTX727, Itacitinib, Ruxolitinib - MDS/MPN | Phase 1 / Phase 2 | Recruiting | Michael Savona | 94 | 2021-11-24 | 2026-10-29 |
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) itacitinib - Myelofibrosis, Polycythemia Vera | Phase 2 | Completed | Incyte Corporation | 4 | 2021-07-12 | 2025-09-02 |
| A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib itacitinib - Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans) | Phase 2 | Terminated | Incyte Corporation | 18 | 2021-03-10 | 2026-06-26 |
| Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD Itacitinib, Extracorporeal Photopheresis (ECP) - Chronic Graft-versus-host-disease | Phase 2 | Terminated | University of Utah | 3 | 2021-01-29 | 2024-01-22 |
| Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Fludarabine - Allogeneic Stem Cell Transplant Recipient, Hematologic and Lymphocytic Disorder | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2020-09-22 | 2020-10-29 | |
| A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy Itacitinib, Immune effector cell therapy, Placebo - Cytokine Release Syndrome | Phase 2 | Completed | Incyte Corporation | 112 | 2020-02-07 | 2024-03-26 |
| Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation Itacitinib - Bronchiolitis Obliterans Syndrome | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 23 | 2020-02-04 | 2025-10-20 |
| Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects Itacitinib, Corticosteroids - Acute Graft-versus-host Disease | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 2 | 2019-12-31 | 2025-11-04 |
| Itacitinib + Everolimus in Hodgkin Lymphoma Itacitinib, Everolimus - Classical Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Pennsylvania | 23 | 2019-02-11 | 2026-06-23 |
| GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Itacitinib, Placebo, Methylprednisolone - Chronic Graft-versus-host Disease | Phase 2 / Phase 3 | Terminated | Incyte Corporation | 155 | 2019-01-17 | 2025-10-20 |
| A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis Itacitinib, Placebo - Moderate to Severe Ulcerative Colitis | Phase 2 | Withdrawn | Incyte Corporation | 2018-09-20 | 2019-12-06 | |
| Relieving Chronic Itch: Oral Medication INCB039110 - Pruritis | Phase 2 | Withdrawn | Washington University School of Medicine | 2018-08-01 | 2019-05-13 | |
| Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer Itacitinib, Pembrolizumab - Non Small Cell Lung Cancer | Phase 2 | Terminated | University of Pennsylvania | 23 | 2018-06-18 | 2023-09-13 |
| A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis Itacitinib, Ruxolitinib - MPN (Myeloproliferative Neoplasms) | Phase 2 | Completed | Incyte Corporation | 23 | 2018-01-26 | 2022-06-16 |
| A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma itacitinib, ibrutinib - Lymphoma | Phase 1 / Phase 2 | Completed | Incyte Corporation | 33 | 2016-12-29 | 2023-06-15 |
| An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer Itacitinib, Osimertinib - Lung Cancer | Phase 1 / Phase 2 | Completed | Incyte Corporation | 59 | 2016-12-20 | 2026-02-09 |
| A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Parsaclisib, Itacitinib, Rituximab - B-Cell Malignancies | Phase 1 / Phase 2 | Completed | Incyte Corporation | 88 | 2016-09-22 | 2023-09-28 |
| INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma INCB040093 Monotherapy, INCB040093, itacitinib - Refractory Hodgkin Lymphoma, Recurrent Adult Hodgkin's Lymphoma | Phase 2 | Terminated | Incyte Corporation | 8 | 2015-06-01 | 2018-01-12 |
Showing 20 of 27. Sign in to see all of them.
Primary Myelofibrosis (5) · Bronchiolitis Obliterans Syndrome (4) · Carcinoma, Non-Small-Cell Lung (4) · Myeloproliferative Disorders (4) · Hematologic Diseases (2) · Hematologic Neoplasms (2) · Neoplasm Metastasis (2) · Arthritis, Rheumatoid (1) · Bronchiolitis Obliterans (1) · Colitis, Ulcerative (1) · Cytokine Release Syndrome (1) · Graft vs Host Disease (1) · Hodgkin Disease (1) · Inflammatory Bowel Diseases (1) · Inhibition, Psychological (1)
Incyte Corporation (19) · M.D. Anderson Cancer Center (2) · University of Pennsylvania (2) · City of Hope Medical Center (1) · Michael Savona (1) · University of Utah (1) · Washington University School of Medicine (1)
United States (24) · Canada (5) · Spain (5) · Austria (4) · Belgium (4) · Germany (4) · Italy (4) · France (2) · Greece (2) · Israel (2) · Poland (2) · United Kingdom (2) · Australia (1) · Denmark (1) · Finland (1)
Peter Langmuir, MD (3) · Peter Langmuir (2) · Rodica Morariu-Zamfir, MD (2) · Victor Sandor, MD (2) · Albert Assad, M.D. (1) · Albert Assad, MD (1) · Amit Pande, M.D. (1) · Brian Kim, MD/MTR (1) · Catherine Lee, MD (1) · Claudia Corrado, M.D. (1) · Corey Langer, MD (1) · Ekaterine Asatiani, M.D. (1) · Gerard T. Kennealey, M.D. (1) · Jakub Svoboda, MD (1) · Kevin O'Hayer, MD (1)
PMID 27789678, PMID 30115734, PMID 30803990, PMID 32998963, PMID 40090005
2017 (2), 2018 (2), 2019 (1), P30CA033572 (1)